This section describes the risk characterization on human health specified in paragraphs
5.3.12, 5.3.13 and section 6.3 of Procedure (G9).
5.1 In risk characterization for human health, the procedure is to compare the exposure
levels to which the target groups are exposed or likely to be exposed with those levels
at which no toxic effects from the chemicals are expected to occur.
5.2 A quantitative risk assessment is an iterative process and normally includes four
steps:
-
.1 Hazard identification – what are the substances of concern and what are
their effects?
-
.2 Dose (concentration) – response (effect) relation – what is the
relationship between the dose and the severity or the frequency of the effect?
-
.3 Exposure assessment – what is the intensity, and the duration or
frequency of exposure to an agent?
-
.4 Risk characterization – how to quantify the risk from the above
data?
5.3 In assessing an acceptable level of a particular substance, the procedure usually
follows moving from animal experiments or preferably human data (e.g. epidemiological
studies) giving a No Observed Adverse Effect Level (NOAEL) or a Lowest Observed Adverse
Effect Level (LOAEL) to derive an exposure limit above, which humans should not be
exposed to (Derived No Effect Level – DNELs). Taking into account the critical health
effect that can be exerted by a threshold mode of action, the lowest DNEL for each
exposure route should be established by dividing the value of the critical dose
descriptor, e.g. N(L)OAEL, by an assessment factor (AF) to allow for extrapolation from
experimental data to real human exposure situations. Comparison of this exposure limit
with a measured or estimated exposure level is then used to judge whether the situation
is satisfactory or whether risk management measures are required.
5.4 Based on the most suitable N(L)OAEL, a DNEL for further risk assessment is derived.
Generally, the DNEL is determined by applying an Assessment Factor (AF) according to the
formula:

5.5 Two groups of potentially exposed persons are distinguished as follows:
5.6 Particularly in case of occupational exposure, it is of primary importance to fully
understand the processes and unit operations in which exposure occurs, and the actual
activities resulting in exposure (potentially exposed individuals, frequency and
duration of the routes of concern, what personal protective equipment and control
measures are used to reduce or mitigate exposure, and how effective they are).
5.7 It is useful to conduct an assessment using "worst-case" assumptions. If this
indicates a risk of no concern, the assessment needs no further refinement.
5.8 Exposure should always be assessed in the first instance for the unprotected worker
and, if appropriate, a second assessment, should be made taking personal protective
equipment (PPE) into account.
5.9 In the risk characterization, these estimates are combined with the results of the
effects assessment and conclusions are drawn whether or not there is a concern for any
scenarios assessed (Risk Characterization Ratio (RCR) = Exposure/DNEL).
5.10 When a risk assessment results in the conclusion that there is an unacceptable risk
(RCR > 1), a second Tier assessment should be performed by considering specific risk
control measures in order to lower this risk to acceptable levels (protective clothing,
respirators and self-contained breathing apparatus, crew training, good operational
practices, etc.).
5.11 The effect assessment of the Active Substances, Preparations and Relevant Chemicals
should include a screening on carcinogenic, mutagenic and endocrine disruptive
properties, taking into account available information. There is no requirement for
additional testing. If the screening results give rise to concerns, this should give
rise to a further assessment.
5.12 As a general rule, exposure in the workplace must be avoided or minimized as far as
technically feasible. In addition, a risk for the general public from secondary exposure
to a non-threshold carcinogenic substance is also unacceptable.
5.13 Carcinogens can have a threshold or non-threshold mode of action. When it comes to
threshold carcinogens, these can be assessed by using a Derived No-Effect Level (DNEL)
approach, however in the case of the non-threshold carcinogens a different approach to
risk assessment is recommended. In these cases, a Derived Minimal Effect Level (DMEL)
should be determined.
5.14 Cancer risk levels between 10-4 to 10-6 are
normally seen as indicative tolerable risk levels when setting DMELs. Where these values
are available from internationally recognized bodies, they can be used to set DMELs for
risk assessment purposes.
5.15 The assessment of the carcinogenicity, mutagenicity and reproductive toxicity
properties of the Active Substance and the Relevant Chemicals takes place as part of the
PBT assessment (see paragraph 6.1 of this Methodology).
5.16 Forty-one chemicals most commonly associated with treated ballast water (see
appendix 6) have been already assessed by the GESAMP-BWWG. The DNEL and DMEL values can
be found online in the GESAMP-BWWG Database of chemicals most commonly associated with
treated ballast water (https://gisis.imo.org/).
5.17 The human risk assessment approach is described in more detail in appendix 4.